



**Supplemental Digital Content 1. Subject disposition.** PCV13=13-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine. <sup>a</sup>All-available immunogenicity population was defined as all subjects who had at least 1 valid and determinate assay result related to the proposed analysis. <sup>b</sup>Discontinued before the blood draw visit after the PPSV23 dose, except for “other” who discontinued after the blood draw visit after the PPSV23 dose because of pregnancy. <sup>c</sup>Subjects could be excluded for >1 reason; reasons for exclusion from evaluable immunogenicity population include not eligible for study, CD4 HIV window (most recent CD4 count >180 days), received <2 doses of PCV13 in the sequence assigned; no valid assay result after doses of PCV13 and PPSV23 for any serotype.